Drug intelligence / Profile preview

GB24

Development stage: Unknown
Lead developer: Kexing
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GB24 is a monoclonal antibody developed by Shandong Kexing Bioproducts (Kexing Biopharm) for the treatment of inflammatory bowel diseases, specifically ulcerative colitis. As of 2024, the drug is in Phase 3 clinical development. It is part of Kexing Biopharm's innovative biologics pipeline, which focuses on therapeutic areas such as immunology and digestion. While the specific molecular target is not explicitly disclosed in the provided pipeline summaries, the drug is designed to modulate the inflammatory response characteristic of ulcerative colitis.

Other names: monoclonal antibody for ulcerative colitis

Beyond the preview

Go deeper on GB24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB24.

Explore the full profile